Cargando…

Female Reproductive Factors and Differentiated Thyroid Cancer

Differentiated thyroid cancer (DTC) is markedly more common in women than men, the highest female-to-male ratio being recorded during the reproductive period. This evidence has led to the suggestion that female hormonal and reproductive factors may account for the observed DTC gender disparity. This...

Descripción completa

Detalles Bibliográficos
Autores principales: Moleti, Mariacarla, Sturniolo, Giacomo, Di Mauro, Maria, Russo, Marco, Vermiglio, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440523/
https://www.ncbi.nlm.nih.gov/pubmed/28588554
http://dx.doi.org/10.3389/fendo.2017.00111
_version_ 1783238076269592576
author Moleti, Mariacarla
Sturniolo, Giacomo
Di Mauro, Maria
Russo, Marco
Vermiglio, Francesco
author_facet Moleti, Mariacarla
Sturniolo, Giacomo
Di Mauro, Maria
Russo, Marco
Vermiglio, Francesco
author_sort Moleti, Mariacarla
collection PubMed
description Differentiated thyroid cancer (DTC) is markedly more common in women than men, the highest female-to-male ratio being recorded during the reproductive period. This evidence has led to the suggestion that female hormonal and reproductive factors may account for the observed DTC gender disparity. This review focuses on current evidence on the risk of DTC in conjunction with major female reproductive factors, including the impact of pregnancy on DTC occurrence and progression/recurrence. Overall, studies exploring the link between the risk of DTC and menstrual and menopausal factors, oral contraceptives and/or hormone replacement therapy, showed these associations, if any, to be generally weak. Nonetheless, there is some evidence that higher levels of exposure to estrogens during reproductive years may confer an increased risk of DTC. As far as pregnancy is concerned, it is unclear whether a potential association between parity and risk of DTC actually exists, and whether it is enhanced in the short-term following delivery. A possible role for pregnancy-related factors in DTC progression has been recently suggested by some reports, the results of which are consistent with a worse outcome in the short-term of women diagnosed with DTC during gestation compared to non-pregnant control patients. Also, some progression of disease has been described in women with structural evidence of disease prior to pregnancy. However, there seems to be no impact from pregnancy in DTC-related death or overall survival. Several in vitro and animal studies have evaluated the influence of estrogens (E) and estrogen receptors (ERs) on thyroid cell proliferation. Presently available data are indicative of a role of E and ERs in thyroid cancer growth, although considerable discrepancies in respect to ER expression patterns in thyroid cancer tissues actually exist. Further studies providing more direct evidence on the possible role of E and of placental hormones and growth factors on thyroid growth may expand our knowledge on the mechanisms beyond the gender disparity of proliferative thyroid diseases.
format Online
Article
Text
id pubmed-5440523
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-54405232017-06-06 Female Reproductive Factors and Differentiated Thyroid Cancer Moleti, Mariacarla Sturniolo, Giacomo Di Mauro, Maria Russo, Marco Vermiglio, Francesco Front Endocrinol (Lausanne) Endocrinology Differentiated thyroid cancer (DTC) is markedly more common in women than men, the highest female-to-male ratio being recorded during the reproductive period. This evidence has led to the suggestion that female hormonal and reproductive factors may account for the observed DTC gender disparity. This review focuses on current evidence on the risk of DTC in conjunction with major female reproductive factors, including the impact of pregnancy on DTC occurrence and progression/recurrence. Overall, studies exploring the link between the risk of DTC and menstrual and menopausal factors, oral contraceptives and/or hormone replacement therapy, showed these associations, if any, to be generally weak. Nonetheless, there is some evidence that higher levels of exposure to estrogens during reproductive years may confer an increased risk of DTC. As far as pregnancy is concerned, it is unclear whether a potential association between parity and risk of DTC actually exists, and whether it is enhanced in the short-term following delivery. A possible role for pregnancy-related factors in DTC progression has been recently suggested by some reports, the results of which are consistent with a worse outcome in the short-term of women diagnosed with DTC during gestation compared to non-pregnant control patients. Also, some progression of disease has been described in women with structural evidence of disease prior to pregnancy. However, there seems to be no impact from pregnancy in DTC-related death or overall survival. Several in vitro and animal studies have evaluated the influence of estrogens (E) and estrogen receptors (ERs) on thyroid cell proliferation. Presently available data are indicative of a role of E and ERs in thyroid cancer growth, although considerable discrepancies in respect to ER expression patterns in thyroid cancer tissues actually exist. Further studies providing more direct evidence on the possible role of E and of placental hormones and growth factors on thyroid growth may expand our knowledge on the mechanisms beyond the gender disparity of proliferative thyroid diseases. Frontiers Media S.A. 2017-05-23 /pmc/articles/PMC5440523/ /pubmed/28588554 http://dx.doi.org/10.3389/fendo.2017.00111 Text en Copyright © 2017 Moleti, Sturniolo, Di Mauro, Russo and Vermiglio. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Moleti, Mariacarla
Sturniolo, Giacomo
Di Mauro, Maria
Russo, Marco
Vermiglio, Francesco
Female Reproductive Factors and Differentiated Thyroid Cancer
title Female Reproductive Factors and Differentiated Thyroid Cancer
title_full Female Reproductive Factors and Differentiated Thyroid Cancer
title_fullStr Female Reproductive Factors and Differentiated Thyroid Cancer
title_full_unstemmed Female Reproductive Factors and Differentiated Thyroid Cancer
title_short Female Reproductive Factors and Differentiated Thyroid Cancer
title_sort female reproductive factors and differentiated thyroid cancer
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440523/
https://www.ncbi.nlm.nih.gov/pubmed/28588554
http://dx.doi.org/10.3389/fendo.2017.00111
work_keys_str_mv AT moletimariacarla femalereproductivefactorsanddifferentiatedthyroidcancer
AT sturniologiacomo femalereproductivefactorsanddifferentiatedthyroidcancer
AT dimauromaria femalereproductivefactorsanddifferentiatedthyroidcancer
AT russomarco femalereproductivefactorsanddifferentiatedthyroidcancer
AT vermigliofrancesco femalereproductivefactorsanddifferentiatedthyroidcancer